Viatris Inc. Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Viatris Inc. is a global healthcare company operating in four reportable segments: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company focuses on branded and generic medicines, including complex products, with operations in over 165 countries.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $3,517.0 million | $3,254.3 million |
| Net Sales | $3,509.7 million | $3,243.2 million |
| Gross Profit | $1,157.2 million | $1,161.2 million |
| Gross Margin | 33% | 36% |
| Net Earnings (Loss) | $176.4 million | $(3,042.0) million |
| Diluted EPS | $0.15 | $(2.55) |
| Adjusted EBITDA | $1,049.5 million | $923.5 million |
| Operating Cash Flow | $388.3 million | $535.5 million |
| Cash and Equivalents | $1,804.2 million | $1,322.4 million |
| Total Debt (Current + Long-term) | $14,344.6 million | $14,413.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 8% year-over-year, driven by an 8% increase in net sales. On a constant currency basis, net sales grew 3%, primarily due to new product sales in Developed Markets and base business growth in Greater China.
- Profitability Turnaround: The company returned to profitability with net earnings of $176.4 million, a significant improvement from the $3.04 billion net loss in Q1 2025. The prior year loss was heavily impacted by a $2.94 billion goodwill impairment charge, which did not recur in Q1 2026.
- Margin Compression: GAAP gross margin decreased from 36% to 33%. This was driven by higher costs of sales, including $71.9 million in charges related to a fire at the Nashik, India manufacturing facility and increased restructuring costs.
- Segment Performance:
- Developed Markets: Net sales up 7% (1% constant currency).
- Greater China: Net sales up 22% (18% constant currency), driven by e-commerce and retail growth.
- JANZ: Net sales down 1% (2% constant currency) due to price reductions and competition.
- Emerging Markets: Net sales up 3% (flat constant currency).
Guidance, Outlook, and Risks
- Restructuring Program: In February 2026, Viatris announced an Enterprise-Wide Strategic Review (EWSR) targeting a global workforce reduction of up to 10%. The company expects total pre-tax charges between $700 million and $850 million, with anticipated savings of $600 million to $700 million once fully implemented.
- Manufacturing Disruptions:
- Nashik Fire: A fire in February 2026 caused $71.9 million in charges. Full operations are expected to resume in July 2026.
- Indore Facility: The facility remains under FDA import alert. The company anticipates readiness for reinspection in 2026.
- Divestiture: The company completed the sale of its Compulsory Convertible Preferred Shares (CCPS) in Biocon Biologics in Q1 2026 for $815 million ($400 million cash, $415 million equity).
- Litigation: Significant accruals exist for drug pricing matters ($60.8 million), opioid settlements ($281.3 million), and other contingencies. The company has reached a settlement framework for opioid claims totaling up to $335 million over nine years.
- Capital Allocation: The company declared a quarterly dividend of $0.12 per share. No share repurchases were made in Q1 2026, though a $2.0 billion authorization remains active.
Investor Verification Checklist
- Verify the timeline for the resumption of full operations at the Nashik facility and the status of the FDA reinspection for the Indore facility.
- Monitor the execution of the 2026 Restructuring Program to ensure cost savings materialize as projected ($600M-$700M).
- Review the status of the Biocon equity shares received in the divestiture, noting the six-month lock-up period.
- Assess the impact of ongoing litigation, specifically the drug pricing MDL bellwether trials scheduled for late 2026 and 2027.
- Track the progress of the selatogrel and cenerimod development programs, which drove increased R&D expenses.